Lanthio Pharma licenses lanthionine-stabilized Angiotensin agonistic peptide drug to Tarix Pharmaceuticals

23-Feb-2012 - Netherlands

Lanthio Pharma B.V. announced that it has granted Tarix Pharmaceuticals, Inc. an exclusive license to its lanthionine-stabilized Angiotensin-(1-7) agonistic peptide. The commercial terms contain milestone payments and royalties. Tarix will finance further product development.

Lanthionine-stabilized Angiotensin-(1-7) is being developed for the treatment of acute lung injury and related indications with high unmet medical need. It is an agonistic peptide that was discovered by Lanthio Pharma, using its proprietary LanthioPep® technology. The compound is stable and resistant to angiotensin-converting enzyme. Additionally, it has high specificity for the MAS receptor and shows increased intrinsic activity compared to wild-type Angiotensin-(1-7).

Bart Wuurman, CEO of Lanthio Pharma commented; This deal with Tarix presents an early revenue opportunity and further validates the exciting potential of our technology to discover next generation peptide therapeutics that are more stable and more potent than classical peptides and hence have the characteristics that are required for successful innovative therapeutics.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...